OMCL vs. MASI, AMN, WST, HSTM, MDRX, CRTX, HNGE, PRVA, INSP, and ENOV
Should you be buying Omnicell stock or one of its competitors? The main competitors of Omnicell include Masimo (MASI), AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), Veradigm (MDRX), Cortexyme (CRTX), Hinge Health (HNGE), Privia Health Group (PRVA), Inspire Medical Systems (INSP), and Enovis (ENOV).
Omnicell vs. Its Competitors
Masimo (NASDAQ:MASI) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.
Masimo has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
86.0% of Masimo shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 16.9% of Masimo shares are held by insiders. Comparatively, 2.5% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Masimo currently has a consensus target price of $194.60, suggesting a potential upside of 31.19%. Omnicell has a consensus target price of $46.71, suggesting a potential upside of 50.79%. Given Omnicell's higher probable upside, analysts clearly believe Omnicell is more favorable than Masimo.
In the previous week, Masimo had 5 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for Masimo and 2 mentions for Omnicell. Masimo's average media sentiment score of 1.07 beat Omnicell's score of 1.00 indicating that Masimo is being referred to more favorably in the media.
Omnicell has a net margin of 2.01% compared to Masimo's net margin of -24.85%. Masimo's return on equity of 26.54% beat Omnicell's return on equity.
Omnicell has lower revenue, but higher earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Summary
Masimo beats Omnicell on 11 of the 17 factors compared between the two stocks.
Get Omnicell News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Omnicell Competitors List
Related Companies and Tools
This page (NASDAQ:OMCL) was last updated on 10/22/2025 by MarketBeat.com Staff